The HBV Forum 14 was held in Amsterdam, The Netherlands on Tuesday, May 6, 2025
Materials
Introductory Remarks and Program Overview
Welcome, Program Overview, and Acknowledgments
Ekene Osakwe, Forum for Collaborative Research*
Steering Committee Co-Chair Welcome Remarks
Veronica Miller, Forum for Collaborative Research
Norah Terrault, Keck Medicine of USC
Terry Wright, GSK*
Session I: Roundtable Updates
Rapid Fire Industry Updates
Industry Participants
Immune Checkpoint Inhibitor Working Group Update
Mitchell Leus, Forum for Collaborative Research
HBV Clinical Research in Africa Working Group Update
Ekene Osakwe, Forum for Collaborative Research*
Standardizing HBV Nomenclature Update
Chari Cohen, Hepatitis B Foundation
Veronica Miller, Forum for Collaborative Research
Session II: HBV Cure Endpoints: Time to Reconsider?
Is it time to rethink our language in HBV?
Jordan Feld, Toronto Centre for Liver Disease
Panel Discussion
Stephanie Buchholz, European Medicines Agency
Chari Cohen, Hepatitis B Foundation
Adam Gehring, Schwartz Reisman Liver Research Centre
Seng Gee Lim, National University Health System, Singapore
Norah Terrault, Keck Medicine of USC
Fabien Zoulim, Lyon Hepatology Institute, IHU EVEREST
Open Discussion
All Meeting Participants
Session III: Gene Editing and Epigenetic Approaches for HBV Cure
Panel Discussion
Kendra Congdon, Tune Therapeutics
Emily Harrison, Precision BioSciences
Tracy McGregor, nChroma Bio
Bob Zhang, Epigenic Therapeutics
Session IV: HBV and Steatotic Liver Disease
MASLD in patients with chronic hepatitis B: impact on clinical outcomes and response to antiviral therapy
Milan Sonneveld, Erasmus University Medical Center
Panel Discussion
Marc Ghany, NIH/NIDDK*
Paul Kwo, Stanford University
Seng Gee Lim, National University Health System, Singapore
Wendy Spearman, University of Cape Town
Open Discussion
All Meeting Participants
Session V: HIV/HBV Co-infection
Challenges and opportunities in HBV cure drug development in people living with HIV/HBV
Debika Bhattacharya, University of California, Los Angeles*
Clinical Virology Regulatory Perspective on HIV/HBC Co-infection
Eric Donaldson, U.S. FDA, Center for Drug Evaluation and Research*
Panel Discussion
Stephanie Buchholz, European Medicines Agency
Mark Sonderup, University of Cape Town
Chloe Thio, Johns Hopkins University*
David Thomas, Johns Hopkins University
Open Discussion
All Meeting Participants
Meeting Wrap Up and Adjourn
HBV and Transplantation: New Topic Proposal
Norah Terrault, Keck Medicine of USC
New Topics and/or Other Business
All Meeting Participants
* Indicates Remote Participation
.png)


